Nitroglycerin and Sodium Nitroprusside

Mechanism

Pharmacologic Class and Drug Group

Direct vasodilators and synthetic nitric oxide donors. Nitroglycerin is an preferred venodilatory organic nitrate; sodium nitroprusside is a balanced direct arterial and venous vasodilator (inorganic nitrovasodilator)..

Mechanism of Action

Smooth muscle relaxation within the walls of arterial and venous vessels is regulated predominantly by the endothelial nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) signaling pathway within vascular smooth muscle cells.

Molecular Mechanism of Nitric Oxide Donation

1. Nitroglycerin (Enzymatic activation with venodilator profile): An organic nitrate requiring mitochondrial enzymatic reduction by aldehyde dehydrogenase 2 (ALDH2) to release nitric oxide (NO) within venous smooth-muscle cells.

2. Sodium Nitroprusside (Spontaneous light-sensitive breakdown): An inorganic complex with an iron atom coordinated to five cyanide groups and one nitrosyl group. Contact with erythrocytes leads to rapid non-enzymatic nitric oxide release, accounting for its rapid, potent vasodilatory action.

3. Soluble Guanylyl Cyclase (sGC) Pathway and Vasodilation: Free NO stimulates soluble cytoplasmic guanylate cyclase (sGC), increasing cGMP synthesis from cellular GTP:

↑ [cGMP] Activation of Protein Kinase G (PKG) Phosphorylation of Calcium channels and SERCA pumps

Activation of PKG promotes phosphorylation and inhibition of L-type calcium channels (Cav1.2), blunting inward calcium influx, and enhances calcium sequestration into the sarcoplasmic reticulum via phosphorylation of SERCA regulatory proteins. This abruptly decreases free cytosolic calcium, inactivating MLCK and inducing profound smooth muscle relaxation in vascular walls.

4. Differential vasoselective effect:

• Nitroglycerin: At conventional low doses, predominantly dilates venous capacitance vessels. This reduces venous return, left ventricular preload and myocardial wall stress, lowering oxygen demand. Higher doses also cause systemic arterial dilation.
• Sodium Nitroprusside: Produces potent arterial and venous dilation, reducing both preload and afterload with a rapid, dose-dependent fall in blood pressure.

Pharmacokinetics

High-Resolution Pharmacokinetics

• Nitroglycerin (Sublingual / Intravenous): It presents an absolute first-pass hepatic clearance (oral bioavailability < 1% due to the action of the gastric and hepatic nitrate reductase enzyme), which prevents its conventional oral intake (requires sublingual transmucosal absorption or direct intravenous infusion). Its plasma elimination half-life is only 1 to 3 minutes, with a duration of its local biological effect of 10-20 minutes after the sublingual bolus.
• Sodium Nitroprusside: It is administered exclusively by continuous intravenous route with an infusion pump. Its onset of action is immediate (in seconds), reaching its maximum peak in 1 to 2 minutes of infusion. When the pump is stopped, the tension effect disappears completely within 3 to 5 minutes. Complex metabolism of cyanide to thiocyanate in the liver.

Indicators and dose

Clinical Indications and Uses

• Acute Phase of Ischemic Heart Disease (Unstable Angina / AMI): Sublingual nitroglycerin or continuous intravenous infusion for the immediate control of anginal and ischemic pain.
• Acute Lung Edema Associated with Heart Failure: Intravenous nitroglycerin to rapidly reduce preload and relieve retrograde pulmonary congestion.
• Urgent Hypertensive Crises with Organ Damage (Dissecting aortic aneurysm / Hypertensive encephalopathy): Sodium nitroprusside by intravenous infusion controlled with a pump for the controlled decrease in blood pressure.

Dosage and Clinical Adjustment

Nitroglycerin:

• Sublingual (Acute Anginous Pain): 0.4 mg to 0.8 mg sublingual every 5 minutes, up to a maximum of three consecutive doses within 15 minutes of clinical suspicion.
• Intravenous infusion: Start with 5 µg to 10 µg/minute in continuous infusion, titrating upwards in steps of 5-10 µg/minute every 3-5 minutes according to the patient's hemodynamic and blood pressure response.

Sodium Nitroprusside:

• Hypertensive Crisis: Start with 0.3 µg/kg/minute in continuous intravenous infusion with an infusion pump. Maximum recommended maintenance dose of 10 µg/kg/minute. The infusion bottle must be strictly protected from direct light by wrapping it in opaque aluminum foil (due to its extreme photo-sensitivity, since exposure to light accelerates the degradation and release of cyanide in the bottle).

Security

Absolute and Relative Contraindications

Contraindications of Nitroglycerin

• Basal profound arterial hypotension or shock of cardiogenic origin.
• Confirmed right ventricular infarction: Venous vasodilation drastically decreases venous return, fatally collapsing volume-dependent cardiac output in these patients.
• Concomitant use of Phosphodiesterase 5 Inhibitors (Sildenafil, Tadalafil): Massive synergism of cGMP accumulation that causes lethal refractory cardiovascular collapse.

Contraindications of Nitroprusside

• Advanced kidney or liver failure (critical risk of accumulation and toxicity from cyanide and thiocyanate metabolites).
• Compensatory arterial hypertension (coarctation of the aorta or arteriovenous shunt).
• Elevated baseline intracranial pressure.

Adverse Effects and Specific Toxicity

• Intense Pulsating Headache (Nitroglycerin 30%): Secondary to direct vasodilation of the meningeal arteries. It resolves with conventional analgesics.
• Orthostatic Hypotension and Reflex Tachycardia: Requires caution when incorporating the patient.
• Nitrate Tolerance (Tachyphylaxis): The continuous infusion of nitroglycerin over 12-24 hours depletes the cellular sulfhydryl groups necessary for its bioactivation by ALDH2, progressively attenuating its dilating effect. Requires nitrate-free periods of 10-12 hours a day in chronic treatments.
• Cyanide and Thiocyanate Toxicity (Nitroprusside - Critical RAM):

Critical Toxicity: Pathophysiology of Nitroprusside Cyanide Intoxication

Each molecule of sodium nitroprusside spontaneously releases 5 cyanide ions into the capillary plasma. Cyanide is taken up by the liver and conjugated by the mitochondrial enzyme rhodanase together with sulfur donors to form thiocyanate (100 times less toxic metabolite, eliminated through the kidneys). If high doses of nitroprusside are infused over a prolonged period, sulfur reserves are depleted, and free cyanide accumulates. Free cyanide irreversibly blocks cytochrome c oxidase of the mitochondrial electron transport chain:

Cyanide Accumulation Cytochrome c Oxidase Blockade Tissue Anoxia and Severe Lactic Acidosis

It is clinically manifested by metabolic acidosis with unexplained elevated GAP anion, psychomotor agitation, bitter almond breath, mental confusion and cardiovascular collapse. Management requires immediate discontinuation of the drug and administration of hydroxocobalamin (Vitamin B12a), which selectively binds to plasma cyanide to form non-toxic cyanocobalamin, safely eliminated in urine.

Relevant Drug Interactions

• PDE5 inhibitors (Sildenafil): Sildenafil blocks the degradation of cGMP. If co-administered with an NO donor (nitroglycerin), the accumulation of cGMP is massive and uncontrollable, inducing profound hypotension and shock that is difficult to manage:

Safety Pearl: Nitrate Exclusion Interval after Use of I-PDE5

When presenting with acute chest pain in the emergency department, it is mandatory to actively question the patient about recent use of phosphodiesterase 5 inhibitors for erectile dysfunction before administering nitroglycerin. The following exclusion deadlines must be strictly complied with:

Use of Sildenafil Exclude Nitrates for at least 24 hours Use of Tadalafil Exclude Nitrates for at least 48 hours

In this way, the risk of deleterious synergistic interactions on blood pressure and perfusion of vital organs is prevented.